Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 719-731

  Ferreira, José Alexandre ^a,b   Videira, Paula A ^c   Lima, Luís ^b,d,e,f   Pereira, Sofia ^b,g   Silva, Mariana ^c   Carrascal, Mylène ^c   Severino, Paulo F ^c,h   Fernandes, Elisabete ^b   Almeida, Andreia ^a,b   Costa, Céu ^b,g   Vitorino, Rui ^a   Amaro, Teresina ⁱ   Oliveira, Maria J ^d,j,k   Reis, Celso A ^a,d   Dall'Olio, Fabio ^h   Amado, Francisco ^a   Santos, Lúcio Lara ^b,g  

^a UNIVERSITY OF AVEIRO   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^f LPCC Research Department Portuguese League Against Cancer (LPCC NRN)   (Portugal)

^g UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ HOSPITAL PEDRO HISPANO   (Portugal)

^j INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^k University of Porto   (Portugal)

more..

Author keywords

Bladder cancer; Glycosylation; Proliferative bladder cancer; Sialyl Tn; ST6GalNAc.I; Tumour associated glycans

Indexed keywords

CARBOHYDRATE ANTIGEN; SIALIC ACID; SIALYLTRANSFERASE; TUMOR ANTIGEN; TUMOR ASSOCIATED CARBOHYDRATE ANTIGEN SIALYL TN; UNCLASSIFIED DRUG;

ACETYLATION; ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTECTOMY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; STABLE EXPRESSION; UROTHELIUM;

EID: 84878107131     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.03.001     Document Type: Article

References (66)

1. Angata T., Tabuchi Y., Nakamura K., Nakamura M. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology 2007, 17:838-846.
2. Askeland E.J., Newton M.R., O'Donnell M.A., Luo Y. Bladder cancer immunotherapy: BCG and beyond. Adv. Urol. 2012, 2012:181987.
3. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Bohle A., Palou-Redorta J., Roupret M. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Actas Urol. Esp. 2012, 36:389-402.
4. Baldus S.E., Zirbes T.K., Monig S.P., Engel S., Monaca E., Rafiqpoor K., Hanisch F.G., Hanski C., Thiele J., Pichlmaier H., Dienes H.P. Histopathological subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: Sialosyl-Lewis(a), Sialosyl-Lewis(x) and sialosyl-Tn. Tumour. Biol. 1998, 19:445-453.
5. Bergeron A., Champetier S., LaRue H., Fradet Y. MAUB is a new mucin antigen associated with bladder cancer. J.Biol. Chem. 1996, 271:6933-6940.
6. Bergeron A., LaRue H., Fradet Y. Biochemical analysis of a bladder-cancer-associated mucin: structural features and epitope characterization. Biochem. J. 1997, 321(3):889-895.
7. Cao Y., Schlag P.M., Karsten U. Immunodetection of epithelial mucin (MUC1, MUC3) and mucin-associated glycotopes (TF, Tn, and sialosyl-Tn) in benign and malignant lesions of colonic epithelium: apolar localization corresponds to malignant transformation. Virchows Arch. 1997, 431:159-166.
8. Clement M., Rocher J., Loirand G., Le P.J. Expression of sialyl-Tn epitopes on beta1 integrin alters epithelial cell phenotype, proliferation and haptotaxis. J.Cell Sci. 2004, 117:5059-5069.
9. Conze T., Carvalho A.S., Landegren U., Almeida R., Reis C.A., David L., Soderberg O. MUC2 mucin is a major carrier of the cancer-associated sialyl-Tn antigen in intestinal metaplasia and gastric carcinomas. Glycobiology 2010, 20:199-206.
10. Dall'Olio F., Malagolini N., Trinchera M., Chiricolo M. Mechanisms of cancer-associated glycosylation changes. Front. Biosci. 2012, 17:670-699.
11. Dall'Olio F., Mariani E., Tarozzi A., Meneghetti A., Chiricolo M., Lau J.T., Facchini A. Expression of beta-galactoside alpha 2,6-sialyltransferase does not alter the susceptibility of human colon cancer cells to NK-mediated cell lysis. Glycobiology 1997, 7:507-513.
12. David L., Carneiro F., Sobrinho-Simoes M. Sialosyl Tn antigen expression is associated with the prognosis of patients with advanced gastric cancer. Cancer 1996, 78:177-178.
13. Davidson B., Berner A., Nesland J.M., Risberg B., Kristensen G.B., Trope C.G., Bryne M. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Hum. Pathol. 2000, 31:1081-1087.
14. Dovedi S.J., Davies B.R. Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev. 2009, 28:355-367.
15. Ferreira B., Marcos N.T., David L., Nakayama J., Reis C.A. Terminal alpha1,4-linked N-acetylglucosamine in Helicobacter pylori-associated intestinal metaplasia of the human stomach and gastric carcinoma cell lines. J.Histochem. Cytochem. 2006, 54:585-591.
16. Gilewski T.A., Ragupathi G., Dickler M., Powell S., Bhuta S., Panageas K., Koganty R.R., Chin-Eng J., Hudis C., Norton L., Houghton A.N., Livingston P.O. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin. Cancer Res. 2007, 13:2977-2985.
17. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 2001, 491:369-402.
18. Heimburg-Molinaro J., Lum M., Vijay G., Jain M., Almogren A., Rittenhouse-Olson K. Cancer vaccines and carbohydrate epitopes. Vaccine 2011, 29:8802-8826.
19. Hussain M.H., Wood D.P., Bajorin D.F., Bochner B.H., Dreicer R., Lamm D.L., O'Donnell M.A., Siefker-Radtke A.O., Theodorescu D., Dinney C.P. Bladder cancer: narrowing the gap between evidence and practice. J.Clin. Oncol. 2009, 27:5680-5684.
20. Ikeda Y., Kuwano H., Baba K., Ikebe M., Matushima T., Adachi Y., Mori M., Sugimachi K. Expression of sialyl-Tn antigens in normal squamous epithelium, dysplasia, and squamous cell carcinoma in the esophagus. Cancer Res. 1993, 53:1706-1708.
21. Inoue M., Ogawa H., Tanizawa O., Kobayashi Y., Tsujimoto M., Tsujimura T. Immunodetection of sialyl-Tn antigen in normal, hyperplastic and cancerous tissues of the uterine endometrium. Virchows Arch. A Pathol. Anat. Histopathol. 1991, 418:157-162.
22. Itoh T., Yonezawa S., Nomoto M., Ueno K., Kim Y.S., Sato E. Expression of mucin antigens and Lewis X-related antigens in carcinomas and dysplasia of the pharynx and larynx. Pathol. Int. 1996, 46:646-655.
23. Itzkowitz S.H., Yuan M., Montgomery C.K., Kjeldsen T., Takahashi H.K., Bigbee W.L., Kim Y.S. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989, 49:197-204.
24. Jones T.D., Wang M., Eble J.N., MacLennan G.T., Lopez-Beltran A., Zhang S., Cocco A., Cheng L. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin. Cancer Res. 2005, 11:6512-6519.
25. Ju T., Lanneau G.S., Gautam T., Wang Y., Xia B., Stowell S.R., Willard M.T., Wang W., Xia J.Y., Zuna R.E., Laszik Z., Benbrook D.M., Hanigan M.H., Cummings R.D. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 2008, 68:1636-1646.
26. Julien S., Adriaenssens E., Ottenberg K., Furlan A., Courtand G., Vercoutter-Edouart A.S., Hanisch F.G., Delannoy P., Le B.X. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology 2006, 16:54-64.
27. Julien S., Lagadec C., Krzewinski-Recchi M.A., Courtand G., Le B.X., Delannoy P. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. Breast Cancer Res. Treat. 2005, 90:77-84.
28. Julien S., Picco G., Sewell R., Vercoutter-Edouart A.S., Tarp M., Miles D., Clausen H., Taylor-Papadimitriou J., Burchell J.M. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br. J. Cancer 2009, 100:1746-1754.
29. Julien S., Videira P.A., Delannoy P. Sialyl-Tn in cancer: (how) did we miss the target?. Biomolecules 2012, 2:435-466.
30. Kim G.E., Bae H.I., Park H.U., Kuan S.F., Crawley S.C., Ho J.J., Kim Y.S. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology 2002, 123:1052-1060.
31. Kjeldsen T., Clausen H., Hirohashi S., Ogawa T., Iijima H., Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res. 1988, 48:2214-2220.
32. Lakshminarayanan V., Thompson P., Wolfert M.A., Buskas T., Bradley J.M., Pathangey L.B., Madsen C.S., Cohen P.A., Gendler S.J., Boons G.J. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:261-266.
33. Langkilde N.C., Wolf H., Clausen H., Kjeldsen T., Orntoft T.F. Nuclear volume and expression of T-antigen, sialosyl-Tn-antigen, and Tn-antigen in carcinoma of the human bladder. Relation to tumor recurrence and progression. Cancer 1992, 69:219-227.
34. Leivonen M., Nordling S., Lundin J., von B.K., Haglund C. STn and prognosis in breast cancer. Oncology 2001, 61:299-305.
35. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
36. Marcos N.T., Bennett E.P., Gomes J., Magalhaes A., Gomes C., David L., Dar I., Jeanneau C., DeFrees S., Krustrup D., Vogel L.K., Kure E.H., Burchell J., Taylor-Papadimitriou J., Clausen H., Mandel U., Reis C.A. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front. Biosci. (Elite. Ed.) 2011, 3:1443-1455.
37. Marcos N.T., Pinho S., Grandela C., Cruz A., Samyn-Petit B., Harduin-Lepers A., Almeida R., Silva F., Morais V., Costa J., Kihlberg J., Clausen H., Reis C.A. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res. 2004, 64:7050-7057.
38. Margulis V., Lotan Y., Karakiewicz P.I., Fradet Y., Ashfaq R., Capitanio U., Montorsi F., Bastian P.J., Nielsen M.E., Muller S.C., Rigaud J., Heukamp L.C., Netto G., Lerner S.P., Sagalowsky A.I., Shariat S.F. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J.Natl. Cancer Inst. 2009, 101:114-119.
39. Miles D., Roche H., Martin M., Perren T.J., Cameron D.A., Glaspy J., Dodwell D., Parker J., Mayordomo J., Tres A., Murray J.L., Ibrahim N.K. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 2011, 16:1092-1100.
40. Neutsch L., Eggenreich B., Herwig E., Marchetti-Deschmann M., Allmaier G., Gabor F., Wirth M. Lectin bioconjugates trigger urothelial cytoinvasion - a glycotargeted approach for improved intravesical drug delivery. Eur. J. Pharm. Biopharm. 2012, 82:367-375.
41. Numa F., Tsunaga N., Michioka T., Nawata S., Ogata H., Kato H. Tissue expression of Sialyl Tn antigen in gynecologic tumors. J.Obstet. Gynaecol. (Tokyo 1995) 1995, 21:385-389.
42. Ogata S., Koganty R., Reddish M., Longenecker B.M., Chen A., Perez C., Itzkowitz S.H. Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa. Glycoconj. J. 1998, 15:29-35.
43. Ohno S., Ohno Y., Nakada H., Suzuki N., Soma G., Inoue M. Expression of Tn and sialyl-Tn antigens in endometrial cancer: its relationship with tumor-produced cyclooxygenase-2, tumor-infiltrated lymphocytes and patient prognosis. Anticancer Res. 2006, 26:4047-4053.
44. Ozaki H., Matsuzaki H., Ando H., Kaji H., Nakanishi H., Ikehara Y., Narimatsu H. Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin. Exp. Metastasis 2012, 29:229-238.
45. Palmeira C., Lameiras C., Amaro T., Lima L., Koch A., Lopes C., Oliveira P.A., Santos L. CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa. Urol. Oncol. 2011, 29:205-211.
46. Pinho S., Marcos N.T., Ferreira B., Carvalho A.S., Oliveira M.J., Santos-Silva F., Harduin-Lepers A., Reis C.A. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett. 2007, 249:157-170.
47. Pinto R., Carvalho A.S., Conze T., Magalhaes A., Picco G., Burchell J.M., Taylor-Papadimitriou J., Reis C.A., Almeida R., Mandel U., Clausen H., Soderberg O., David L. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. J.Cell Mol. Med. 2012, 16:1474-1484.
48. Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J. Urol. 2009, 27:289-293.
49. Reis C.A., Osorio H., Silva L., Gomes C., David L. Alterations in glycosylation as biomarkers for cancer detection. J.Clin. Pathol. 2010, 63:322-329.
50. Ryan S.O., Turner M.S., Gariepy J., Finn O.J. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res. 2010, 70:5788-5796.
51. Sandmaier B.M., Oparin D.V., Holmberg L.A., Reddish M.A., MacLean G.D., Longenecker B.M. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J.Immunother. 1999, 22:54-66.
52. Santos L., Amaro T., Costa C., Pereira S., Bento M.J., Lopes P., Oliveira J., Criado B., Lopes C. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int. J. Cancer 2003, 105:267-272.
53. Schmitt F.C., Figueiredo P., Lacerda M. Simple mucin-type carbohydrate antigens (T, sialosyl-T, Tn and sialosyl-Tn) in breast carcinogenesis. Virchows Arch. 1995, 427:251-258.
54. Sewell R., Backstrom M., Dalziel M., Gschmeissner S., Karlsson H., Noll T., Gatgens J., Clausen H., Hansson G.C., Burchell J., Taylor-Papadimitriou J. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J.Biol. Chem. 2006, 281:3586-3594.
55. Sievert K.D., Amend B., Nagele U., Schilling D., Bedke J., Horstmann M., Hennenlotter J., Kruck S., Stenzl A. Economic aspects of bladder cancer: what are the benefits and costs?. World J. Urol. 2009, 27:295-300.
56. Sorensen A.L., Reis C.A., Tarp M.A., Mandel U., Ramachandran K., Sankaranarayanan V., Schwientek T., Graham R., Taylor-Papadimitriou J., Hollingsworth M.A., Burchell J., Clausen H. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006, 16:96-107.
57. Terashima S., Takano Y., Ohori T., Kanno T., Kimura T., Motoki R., Kawaguchi T. Sialyl-Tn antigen as a useful predictor of poor prognosis in patients with advanced stomach cancer. Surg. Today 1998, 28:682-686.
58. van der Velden V.H., Hochhaus A., Cazzaniga G., Szczepanski T., Gabert J., van Dongen J.J. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17:1013-1034.
59. van Rhijn B.W., Burger M., Lotan Y., Solsona E., Stief C.G., Sylvester R.J., Witjes J.A., Zlotta A.R. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur. Urol. 2009, 56:430-442.
60. Vazquez-Martin C., Cuevas E., Gil-Martin E., Fernandez-Briera A. Correlation analysis between tumor-associated antigen sialyl-Tn expression and ST6GalNAc I activity in human colon adenocarcinoma. Oncology 2004, 67:159-165.
61. Videira P.A., Calais F.M., Correia M., Ligeiro D., Crespo H.J., Calais F., Trindade H. Efficacy of bacille Calmette-Guerin immunotherapy predicted by expression of antigen-presenting molecules and chemokines. Urology 2009, 74:944-950.
62. Videira P.A., Correia M., Malagolini N., Crespo H.J., Ligeiro D., Calais F.M., Trindade H., Dall'Olio F. ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer 2009, 9:357.
63. Videira P.A., Ligeiro D., Correia M., Trindade H. Gene expression analysis in superficial bladder cancer: comparison of two suitable endogenous reference genes. Curr. Urol. 2007, 1:145-150.
64. Yamamoto M., Yamamoto F., Luong T.T., Williams T., Kominato Y. Expression profiling of 68 glycosyltransferase genes in 27 different human tissues by the systematic multiplex reverse transcription-polymerase chain reaction method revealed clustering of sexually related tissues in hierarchical clustering algorithm analysis. Electrophoresis 2003, 24:2295-2307.
65. Yates D.R., Roupret M. Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy. World J. Urol. 2011, 29:415-422.
66. Zeichner S.B. The failed Theratope vaccine: 10 years later. J.Am. Osteopath. Assoc. 2012, 112:482-483.